UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
UroGen Pharma Stock Performance
Shares of UroGen Pharma stock traded up $0.20 during trading hours on Friday, reaching $8.53. The stock had a trading volume of 55,035 shares, compared to its average volume of 55,212. The firm has a 50 day simple moving average of $7.90 and a two-hundred day simple moving average of $7.43. UroGen Pharma has a 1 year low of $4.85 and a 1 year high of $19.66.
UroGen Pharma (NASDAQ:URGN - Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.11. UroGen Pharma had a negative return on equity of 1,491.69% and a negative net margin of 197.16%. The business had revenue of $13.56 million during the quarter, compared to analyst estimates of $15.62 million. Equities analysts anticipate that UroGen Pharma will post -4.83 earnings per share for the current year.
Analysts Set New Price Targets
Separately, Berenberg Bank assumed coverage on UroGen Pharma in a report on Wednesday, April 27th. They issued a "buy" rating and a $20.00 price objective on the stock.